Behavioral disturbances in dementia by Müller-Spahn, Franz
lthough cognitive decline and deficits in social
competence are the hallmarks of progressive neurode-
generation,behavioral abnormalities are common and
important characteristics of dementia.Alzheimer’s dis-
ease (AD) is the principal cause of dementia in the
elderly,
1 therefore the following review closely relates to
this disorder.It affects almost 15 million people world-
wide.
1A wide range of behavioral disturbances afflict the
majority of patients with dementia. Behavioral distur-
bances, such as verbal or physical aggression, urinary
incontinence, and excessive wandering, are a major
source of caregiver burden and an important contributor
to the decision to admit AD patients to institutionalized
long-term care.
2,3The social and psychological skills and
the compliance of the caregivers,as well as the presence
and competence of the social networkers,determine to a
large extent whether a demented patient with behavioral
problems can live at home or needs nursing home admis-
sion.However,in the past,research in AD focussed pri-
marily on the early detection and management of cogni-
tive deficits,whereas behavioral disturbances have been
neglected.
4
Treatment of behavioral problems can improve the qual-
ity of life of the patient and the carer,and may help avoid
premature institutionalization.
The relationship between these disturbances and the
severity of dementia has not been clarified.There is some
evidence that some symptoms such as depression and
anxiety are more common during slight to moderate
stages, whereas others, eg, behavioral problems like
aggression,seem to occur more in advanced dementia.In
severe stages,significant cognitive impairment becomes
predominant and some behavioral dysfunctions get grad-
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Behavioral disturbances in dementia
Franz Müller-Spahn, MD
A
Psychological symptoms and behavioral abnormalities are
common and prominent characteristics of dementia. They
include symptoms such as depression, anxiety, psychosis,
agitation, aggression, disinhibition, and sleep distur-
bances. Approximately 80% to 90% of patients with
dementia suffer from such behavioral disorders. There are
complex interactions between cognitive deficits, psycho-
logical symptoms, and behavioral abnormalities. A large
number of standardized, reliable, and well-validated
instruments for assessing the behavioral and psychologi-
cal symptoms of dementia have been developed in order
to evaluate the efficacy of treatment. Neurodegenerative
processes in various brain areas, particularly in the fronto-
temporal cortex and limbic regions, leading to choliner-
gic, serotonergic, and noradrenergic neurotransmitter dys-
functions constitute the biological matrix of behavioral
symptoms, whereas psychological factors and personality
traits play a modifying role. A large number of pharma-
cological, psychoeducational, psychotherapeutic, and
social strategies have been developed to improve the
quality of life of patients and their caregivers.
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3 However,many behavioral dis-
turbances like physical violence, incontinence, hitting,
accusatory behaviors,and suspiciousness do not appear
to be closely related to cognitive deficits.
5
There is also controversy about the prevalence of differ-
ent behavioral abnormalities in patients with different
types of dementia.
6 It has been suggested that depression
is more common in vascular dementia than in AD.
6 In a
recent study,only modest differences were found in the
prevalence of mental or behavioral disturbances in dif-
ferent types of dementia or at different stages of illness.
7
The authors investigated a large community population
of elderly people.Patients with AD were more likely to
have delusions and less likely to have depression.
Aberrant motor behavior and agitation/aggression were
more common in patients with advanced dementia.
Epidemiology
The proportion of affected patients has varied among
studies due to differing inclusion and assessment criteria.
These studies suggest that approximately 80% to 90% of
patients with dementia suffer from such behavioral dis-
orders (Table I)
7-14 over the course of their illness.These
rates are considerably higher than those reported in indi-
viduals aged 65 or older without dementia syndrome.
Personality changes are most common in AD and affect
approximately 70% of patients,
8 including disinterest in
environment or inappropriate social behavior.Different
aspects of personality traits may become more predomi-
nant depending on the patient’s primary personality.
Frontotemporal dementia (FTD), a syndrome first
described by more than 100 years ago by Pick,
15 is partic-
ularly dominated by prominent and commonly disturbing
behavior.
16 Early loss of personal and social awareness,
early decline in social interpersonal conduct,early loss of
insight,and emotional blunting are characteristic features
of this dementia type.
16 Mychack and coworkers
16 assessed
41 patients with FTD and concluded from their findings
that right-sided frontotemporal degeneration is associated
with socially undesirable behavior. Symptoms like irri-
tability, impulsiveness, bizarre alterations in dress,
decreased facial expression,and limited and fixed ideas
have been associated with predominantly right temporal
dysfunction
16,17 in patients with FTD.
In addition to primary personality traits,environmental
factors like unfamiliar surroundings may worsen the pro-
gression of AD.
18 In contrast to the negative impact of
deficient social support,a positive atmosphere may affect
the patient’s physical and psychological well-being.
19
Relatives and caregivers often have difficulties in accept-
ing the patient’s loss of established roles and functions in
partnerships or families.
20The caregiver’s skills handling
these problems have a high impact on the development
of psychopathology and behavioral disturbances.
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Selected abbreviations and acronyms
AD Alzheimer’s disease
BEHAVE-AD Behavioral Pathology in Alzheimer’s
Disease Rating Scale
BPSD behavioral and psychological symptoms of
dementia
BRSD Behavioral Rating Scale for Dementia
CMAI Cohen-Mansfield Agitation Inventory
EPS extrapyramidal side effects
FTD frontotemporal dementia
NPI Neuropsychiatric Inventory
SSRI selective serotonin reuptake inhibitor
Table I. Psychological symptomatology and behavioral problems in
dementia, particularly in Alzheimer’s disease. *Dementia of any
etiology; 
†major depression; 
#agitation/aggression; 
§depending on
severity (F. Müller-Spahn, unpublished results).
Prevalence (%)
• Psychological symptomatology
Personality changes 70
8
Depression 24
9† 24
13*
Apathy 72
7 41
9 27
13*
Mania 3.5
9
Anxiety 48
7 17
13*
Delusions 22
7 16
10 18.5
13*
Hallucinations 10
7 17
11 13.5
13*
Irritability 42
7 20.4
13*
Dysphoria 38
7
• Behavioral problems
Agitation 60
7 24
13#
Aggression 20
12
Wandering 19
12
Purposeless activity 40–80
§
Disinhibition 36
7 7
12 9.1
13*
Binge eating 10
12
Hyperorality 6
12
Urinary incontinence 48
12
Aberrant motor behavior 38
7 14.3
13*
Sleep disorders 60–80
§Assessment of psychological and 
behavioral symptoms
The symptoms of dementia can be conceptualized in sev-
eral ways.
18 The most popular dichotomic concept
broadly distinguishes cognitive and noncognitive symp-
toms.
20 Other concepts differentiate between cognitive
dysfunctions and behavioral or psychiatric disturbances.
However, all of these concepts have limitations with
respect to the complex interactions between cognitive
deficits,psychological symptoms,and behavioral abnor-
malities.Recent studies indicate that several noncogni-
tive symptoms are related to the level of cognitive dys-
function among patients with AD.
21,22 Most notably,
aggression appears to increase with greater cognitive
impairment.
22 Less consistent are data on the association
of mood disorders,psychosis,and severity of cognitive
dysfunctions.To date,the relationship of cognitive and
functional status with disturbed/disturbing behaviors
among dementia patients remains an understudied area.
21
Alois Alzheimer stated in the case description of Auguste
D.in 1906 that behavioral disturbances like screaming,
paranoid ideations,hallucinations,and sexual disinhibi-
tion were prominent features of this dementia type.
23
The basis of the diagnosis of behavioral and psycholog-
ical symptoms of dementia (BPSD) comprises a clinical
interview,direct observation of the patient with demen-
tia, and/or a proxy report from a carer or other
observers.
24
Although more than 100 rating scales for the assessment
of BPSD exist, neither the International Statistical
Classification of Diseases,10th Revision (ICD-10) nor the
Diagnostic and Statistical Manual of Mental Disorders,
Fourth Edition (DSM-IV) provide detailed definitions of
behavioral disturbances in dementia.
25 ICD-10 dementia
diagnosis include syndromes like predominantly depres-
sive,delusional,hallucinatory,or mixed symptoms.
A large number of instruments for assessing BPSD have
been developed,particularly in order to evaluate the effi-
cacy of treatment of behavioral disturbances in patients
with probable AD.
In this article,several standardized,reliable,well-validated,
easily applicable,and internationally used rating scales will
be briefly introduced (Table II):the Behavioral Pathology
in Alzheimer’s Disease Rating Scale (BEHAVE-AD),
26
the Cohen-Mansfield Agitation Inventory (CMAI),
27,28 the
Neuropsychiatric Inventory (NPI),
29 and the Behavioral
Rating Scale for Dementia (BRSD).
30
The BEHAVE-AD scale can be completed in a short
period of time (20 min). Reisberg et al
26 identified 25
symptoms in 7 major categories or clusters of psycho-
logical and behavioral disturbances.The second part of
the BEHAVE-AD comprises a global rating of the sever-
ity of the BPSD.There is a large variability of the differ-
ent symptoms at the different stages of AD.
31 Most of the
behavioral symptoms occur at later stages of the disease.
The NPI is a relatively brief assessment instrument that
evaluates a wide range of psychopathologies, and their
severity and frequency of symptoms.It helps to differen-
tiate between dementias.It requires 10 min to perform.
The BRSD from the CERAD (Consortium to Establish a
Registry for Alzheimer’s Disease) considers a wide vari-
ety of symptoms in 8 areas.The BRSD was developed for
the assessment of AD patients with mild to moderate cog-
nitive impairment.
30 It takes 20 to 30 min to administer.
The CMAI
27,28 is a 7-point rating scale that assesses the fre-
quency with which patients manifest up to 29 agitated
behaviors and takes 10 to 15 min to perform.The behavioral
symptoms assessed by the CMAI are listed in Table II.
The comprehensive assessment of the effects of drug
treatment on behavior should include not only those
instruments designed to assess behavioral abnormalities
in dementia,but also rating scales that measure cognitive
changes and health-related quality of life.
3 For example,
the use of antipsychotics, benzodiazepines, or anticon-
vulsants may substantially reduce an undesirable behav-
ior,but may cause sedation and impair cognitive perfor-
mance and the ability to perform activities of daily living.
Therefore,a proper assessment should include cognitive,
behavioral,and quality of life domains.
3 Many of the psy-
chological symptoms and behavioral problems are likely
to be responsive to pharmacological interventions or
nonpharmacological management.
Etiology
The behavioral symptoms seen in dementia (Table II) are
not due to an uniform etiology.
18They are often multifac-
torial and related to the severity of the disease. Loss of
neurons has been considered as a major pathophysiologi-
cal hallmark in AD.These include not only nerve cells of
association cortices,but also neurons of certain nuclei like
cholinergic cells of the dorsal raphe. In addition to the
decrease in cholinergic and serotonergic activity, alter-
ations in the noradrenergic systems occur; these are
reflected by a decrease in the norepinephrine level and an
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4-hydroxyphenylglycol.
32The extent of deficits in seroton-
ergic,cholinergic,and noradrenergic neurotransmission
varies depending on the progression of the neurodegen-
eration and the functional integrity of other neuro-
transmitter systems.
18 Neuropathological alterations and
changes in brain metabolism in the mesotemporal and
frontal brain areas appear to be related to psychotic symp-
toms (Table III).
33-37
Primary personality,behavior of the caregiver,and social
environment largely influence the pattern of behavioral
disturbances.
In conclusion, neurodegenerative processes in various
brain areas,including neurotransmitter dysfunctions,con-
stitute the biological substrate of behavioral symptoms,
whereas psychological factors and personality play a
modifying role.
Psychosis
Delusions and hallucinations are common and promi-
nent features of dementia,and were even described by
Alzheimer.
23They are usually manifest for the first time
in patients with moderate cognitive decline and tend to
disappear in severe stages of dementia probably due to
the inability to articulate psychotic experience.They tend
to recur or persist for several years in the majority of
patients.
38 Delusions and hallucinations may be associ-
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Table II. Clusters assessed by the Behavioral Pathology in Alzheimer’s Disease Rating Scale (BEHAVE-AD),
26 the Cohen-Mansfield Agitation Inventory
(CMAI),
27,28 the Neuropsychiatric Inventory (NPI),
29 and the Behavioral Rating Scale for Dementia (BRSD).
30 CERAD, Consortium to Establish a
Registry for Alzheimer’s Disease.
Cohen-Mansfield Agitation Inventory (CMAI)—Long Form
• Pace, aimless wandering
• Inappropriate dress or disrobing
• Spitting (including at meals)
• Cursing or verbal aggression
• Constant unwarranted request for attention or help
• Repetitive sentences or questions
• Hitting (including self)
• Kicking
• Grabbing onto people
• Pushing
• Throwing things
• Strange noises (weird laughter or crying)
• Screaming
• Biting
• Scratching
• Trying to get to a different place (eg, out of room or building)
• Intentional falling
• Complaining
• Negativism
• Eating/drinking inappropriate substances
• Hurt self or others (cigarette, hot water, etc)
• Handling things inappropriately
• Hiding things
• Hoarding things
• Tearing things or destroying property
• Performing repetitious mannerisms
• Making verbal sexual advances
• Making physical sexual advances
• General restlessness
Behavioral Pathology in Alzheimer’s Disease Rating Scale
(BEHAVE-AD)
• Paranoid and delusional symptoms
• Hallucinations
• Activity disturbances
• Aggressiveness
• Diurnal rhythm disturbances
• Affective disturbances
• Anxieties and phobias
Neuropsychiatric Inventory (NPI)
• Delusions
• Hallucinations
• Agitation, dysphoria
• Anxiety
• Apathy
• Irritability
• Euphoria
• Disinhibition
• Aberrant motor behavior
• Nighttime behavior disturbances
• Appetite and eating abnormalities
CERAD Behavioral Rating Scale for Dementia (BRSD)
• Depressive features
• Psychotic features
• Defective self-regulation
• Irritability and agitation
• Vegetative features
• Apathy
• Aggression
• Affective labilityated with agitation and aggression in AD patients.
39
Misidentification phenomena are frequent;delusions are
typically paranoid type and noncomplex.
40
Schneiderian first-rank symptoms are extremely rare in
AD patients.
40 Jeste and Finkel
40 compared clinical fea-
tures of psychosis in AD with schizophrenia in elderly
patients.In contrast to AD patients,elderly patients with
schizophrenia have a past history of psychotic episodes,
their long-term course is generally stable,and delusions
are frequently bizarre or complex.These authors believe
that psychosis in AD is a distinct syndrome that is
markedly different from schizophrenia in the elderly.
Approximately 30% to 50% of AD patients show psy-
chotic symptoms.
41 Delusions appear to be more frequent
than hallucinations in AD patients (10% to 70% of
patients have delusions while only 3% to 33% have hal-
lucinations).
42 Hallucinations in AD are more commonly
visual than auditory.
40
The cumulative 4-year incidence of new-onset psychosis
in AD patients has been calculated to be 51% (Figure 1).
43
There is some evidence of clinical and neurobiological
differences between AD patients with and without psy-
chotic symptoms.
40 Those with psychosis had greater
impairment on neuropsychological tests preferentially
testing frontal lobe functions.
44 Psychosis in AD patients
was associated with a higher prevalence of extrapyrami-
dal signs.
45 On the basis of neurochemical and neu-
ropathological investigations,those with psychotic symp-
toms had increased neurodegenerative alterations in the
cortex and reduced cortical and subcortical serotonin.
46
Lopez et al
47 reported of a more rapid rate of cognitive
decline as measured by the Mini-Mental State Examination
(MMSE)
48 and a specific deficiency in respective language
in AD patients with delusions and hallucinations than in
patients without such symptoms.Analysis of electroen-
cephalograms (EEGs) showed a significantly greater pro-
portion of moderately abnormal EEGs with an increased
amount of delta and theta activity.These findings suggest
that AD patients with psychotic symptoms have a greater
degree of cerebral dysfunction and more focal neuropsy-
chological defects.
47 Cummings
34 suggested that lesions in
the right temporal cortex might cause abnormal percep-
tual input to the limbic system thus leading to,or facili-
tating the development of,psychotic symptoms.In con-
clusion,these studies suggest a neuropathological basis
for psychosis in AD.
Although antipsychotics have been found to be the treat-
ment of choice for behavioral disturbances,particularly
in nursing facilities,
49 a meta-analysis of 33 controlled tri-
als comparing conventional antipsychotics with placebo
in elderly, severely demented patients with agitation
showed only moderate superiority to placebo.
50 Despite
the extensive use of traditional neuroleptics, such as
haloperidol,the risks may overweigh clinical benefits.
There is much evidence suggesting a high incidence rate
of extrapyramidal side effects (EPS) in patients with
dementia exposed to traditional antipsychotics.Even at
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Table III. Neuropathological basis of behavioral disturbances in dementia.
Symptomatology Neurobiological  basis
Psychosis Degeneration in mesotemporal and frontal brain areas
33,34
Depression Degeneration of the brain stem aminergic nuclei (especially the locus ceruleus)
35; 
decrease in serotonergic neurotransmission
35
Apathy, communication failure Degeneration in the parahippocampal gyrus, frontal and parietal neocortex, 
hippocampus, and basal nucleus of Meynert
36
Klüver-Bucy syndrome Degeneration in the parahippocampal gyrus and parietal neocortex
36
Agitation, aggression Hypofunction of the serotonin and cholinergic systems, relative hyperfunction of 
dopaminergic and noradrenergic systems resulting from neuropathological changes
36,37
Figure 1. Cumulative incidence of new-onset psychosis of Alzheimer’s dis-
ease (with 95% confidence interval) at 1, 2, 3, 4, and 5 years
after baseline evulation.
Reproduced from reference 43: Paulsen JS, Salmon DP, Thal LJ, et al. Incidence of and
risk factors for hallucinations and delusions in patients with probable AD. Neurology.
2000;54:1965-1971. Copyright © 2000, American Academy of Neurology.
0.4
0.6
0.8
1
0.2
0
Year 0 Year1 Year 2 Year 3 Year 4 Year 5
Cumulative annual incidence of hallucinations 
and delusionslow doses of haloperidol (2 to 3 mg/day), 20% of AD
patients with psychosis and disruptive behaviors devel-
oped moderate to severe EPS.
51The new generation of
antipsychotics has a considerably lower potential for EPS
and is therefore generally recommended for treatment
of psychosis in the elderly,particularly in patients with
dementia (Table IV).
52-55 However, only a few placebo-
controlled studies have been published to date.
52,53 Low
starting doses are recommended (Table IV).
Agitation and aggression
The term agitation is poorly defined and applied to a het-
erogeneous group.Behavioral disturbances in dementia
are often globally described as “agitation”including ver-
bal and physical aggression, wandering, and hoarding.
56
These symptoms create patient and caregiver distress,and
lead to nursing home placement.Agitation is a very com-
mon phenomenon in dementia with various causes,such
as undiagnosed medical problems or pain,environmental
or social factors (eg,overstimulation,unwanted care),drug
side effects,sleep disturbances,delirium,and depression.
57
Wandering is a frequent behavioral problem in patients
with an advanced stage of dementia.Nineteen of the 107
patients with AD studied by Burns et al
12 exhibited exces-
sive walking behavior.This disturbance appears to be
closely linked to the severity of dementia.
Physical aggressiveness is one of the most serious and chal-
lenging behavioral disturbances in dementia with a num-
ber of adverse consequences,including injury,chronic dis-
tress,and patient abuse.
22,58 It is probably the main reason
why physicians are called in to treat.
8 Most studies have
shown that 15% to 20% of patients with dementia develop
violent behavior.
22,59 Interestingly,several studies suggested
a relationship between gender, mood disturbances, psy-
chosis,and the development of aggression.Male gender,
60
delusions and hallucinations,
2,39 more severe dementia,
60,61
moderate to severe depression,
22 caregiver depression,
greater impairment in activities of daily living,
22 sleep dis-
turbances,
62 and limited space to live in
63 have all been
described as risk factors for physically aggressive behavior.
On the neurochemical level,many of the behavioral dis-
turbances and psychological symptoms may be linked to
a serotonergic deficit in the brain.
Treatment of agitation in dementia requires a correct iden-
tification of the underlying physical,environmental,and
psychiatric conditions.Common symptomatic pharmaco-
logical interventions—this is the next step when nonphar-
macological treatment approaches including behavioral
management,environmental modifications,interventions
using sound and light,and social interaction groups
3 fail—
include antipsychotics, selective serotonin reuptake
inhibitors (SSRIs),benzodiazepines,β-blockers,and anti-
convulsants, such as carbamazepine and valproate.
Citalopram and perphenazine were found to be more effi-
cacious than placebo in the treatment of agitation/aggres-
sion and psychosis in demented patients.
64 Neuroleptics,
particularly the conventional ones,are often poorly toler-
ated by patients with dementia. Patients with severe
dementia are at an especially high risk of adverse effects
like EPS,drowsiness,and accelerated cognitive decline.
If benzodiazepines are used, the application of sub-
stances with a relatively short half-life and without active
metabolites is recommended (eg, lorazepam and
oxazepam).Sedation,risk of falls,a negative impact on
cognitive abilities, and in some cases paradox effects
restrict the clinical use of these compounds.
Low-potency neuroleptics with low anticholinergic prop-
erties may be beneficial (eg,10 to 150 mg/day melperone)
(Table V); low-dose new antipsychotics (eg, 1 mg/day
risperidone
52 and 5 mg/day olanzapine
53) have been
reported efficacious against violent behavior.Alternatively
anticonvulsants,in particular carbamazepine
65 and dival-
proex sodium,
66 have been investigated as antiaggressivity
compounds in controlled trials in demented patients with
violent behavior.
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Table IV. Examples for drug treatment of psychosis in patients with dementia.
Compound Average dose (mg/day) Starting dose (mg) Comments
Haloperidol 1–3 0.5 Risk of extrapyramidal side effects
Melperone 50–200 25 Low risk of extrapyramidal side effects
Pipamperone 20–80 10 Low risk of extrapyramidal side effects
Risperidone
52 0.5–2 0.5 (Low) risk of orthostatic hypotension
Olanzapine
53 5–10 2.5 Sedation
Quetiapine
54 50–150 25 Sedation
Clozapine
55 12.5–50 12.5 Risk of confusion, sedation, and agranulocytosisTariot et al
65 assessed the efficacy,safety,and tolerability
of carbamazepine in the treatment of agitation and
aggression associated with severe dementia in a placebo-
controlled trial. Clinical Global Impression (CGI) rat-
ings showed global improvement in 77% of the patients
taking carbamazepine and 21% of those taking placebo.
The mean daily dose of carbamazapine at week 6 was 
304 mg/day (SD=119) with a mean serum level of 5.3
µg/mL.The drug was generally well tolerated.
Divalproex sodium with an average dose at week 6 of
826 mg/day (375–1.375 mg/day with an average level of
45 µg/mL) has been shown superior to placebo (reduced
agitation on the CGI in 68% of patients on valproate vs
52% on placebo; P=0.06). Side effects were generally
rated as mild.
These data suggest that anticonvulsants might be a help-
ful strategy in the treatment of agitation and aggression in
dementia.However,further placebo-controlled trials are
required to explore the clinical efficacy and tolerability of
these compounds,particularly of the new generation of
anticonvulsants.Because aggressive patients do not always
respond to medication (single drug or in combination),
one-to-one nursing in a quiet room is sometimes indicated.
Sleep disturbances
Sleep disturbances in AD patients are characterized by
fragmented sleep or disruption in the day–night sleep
cycle.
8They appear to become progressively worse as the
disease progresses,although the severity of this distur-
bance varies considerably among individual patients.
Apart from the neurodegenerative disease process itself,
various other factors may influence the quality of sleep
including physical or environmental conditions and drug
side effects. Pharmacological conditions and drug side
effects.Pharmacologically,chloralhydrate (250–1000 mg/
24 hours),new nonbenzodiazepine hypnotics,such as zolpi-
dem (5–10 mg at night), an imidazopyridine derivative,
zopiclone (3.75–7.5 mg at night),a cyclopyrrolone-deriva-
tive,and low-potency neuroleptics (eg,melperone 25–75 mg
at night) have been found effective.
20Trazodone,a sedative
antidepressant agent with anxiolytic properties and minor
anticholinergic effects improves sleep disorders (25–75 mg).
However,some patients may develop hypotension.
Anxiety
Anxiety occurs in 50% to 80% of patients with AD.
7,9,13
However,in contrast to agitation,aggression,psychosis,
and depression, anxiety has been less well studied in
patients with dementia.Anxiety and depression coexist
and overlap with various symptoms,such as agitation and
the awareness of the cognitive deficiencies with resulting
helplessness.
The etiology and pathophysiology of anxiety in AD is not
well understood.There is evidence that anxiety is associ-
ated with loss of serotonergic neurons in AD.Antidepres-
sants enhancing serotonergic activity,particularly SSRIs,
may improve depression and anxiety.
Benzodiazepines should be used with caution in demen-
tia with anxiety because of the risk of worsening cogni-
tive abilities, oversedation, gait disturbances, daytime
sleepiness,and paradoxical effects.
The serotonin (5-hydroxytryptamine) 5-HT1A receptor
agonist buspirone,a nonbenzodiazepine that is generally
well tolerated,may be beneficial in the treatment of anx-
iety in dementia.It is used at dosages of 10 to 45 mg/day.
Depression
Symptoms of depression are common in Alzheimer’s dis-
ease,ranging from 20% to 60% in most epidemiological
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Table V. Examples for drug treatment of aggressive behavior in patients with dementia.
Compound Average dose (mg/day) Starting dose (mg) Comments
Lorazepam 0.5–1.5 0.5 Risk of falls
Melperone 25–100 25 Weak or no extrapyramidal side effects
Pipamperone 10–80 10 (Low) risk of extrapyramidal side effects
Chlorprothixene 15–75 15 Sedation, minor extrapyramidal side effects
Risperidone 0.5–1 0.5 (Low) risk of orthostatic hypotension
Olanzapine 5–10 2.5 Sedation
Carbamazepine 100–200 20 Slow dose titration, drug–drug interactions,
risk of sedation
Divalproex sodium 125–1000 125 Risk of sedation, nausea, ataxiastudies,
9,41 and 10% to 30% meet criteria for a major
depressive disorder. Common manifestations include
depressed mood,apathy,lack of interest,agitation,loss
of emotional control (easily upset,tearful,or irritable),
and worries about the future and finances.Depression is
often the first symptom/syndrome of AD.
67 However,it
remains unclear whether depressed mood is an early
manifestation of AD or increases susceptibility through
another mechanism.
68The presence of dementia symp-
toms may impair reporting and recognition of depres-
sion.Depression may result from the patient’s recogni-
tion of the severity of his or her cognitive impairment or
from neurotransmitter dysfunctions associated with the
underlying disease process.
68The discussion on the psy-
chological impact of insight into having AD is contro-
versial. For many investigators, depression in most
patients with AD is not “reactive” to the awareness of
having AD or the disability associated with it.
67,69,70 Major
depression tends to first manifest in AD patients with
mild to moderate cognitive deficiencies,whereas in the
advanced stages of dementia there might be insufficient
brain tissue to maintain any depressive affect.
71
All patients with cognitive decline and depressive symp-
toms should undergo a comprehensive evaluation to
specify the type and cause of depression.
7,72,73 Particular
attention should be paid to the differential diagnosis of
primary dementia with secondary depressive symptoms
from a primary major depressive episode with cognitive
dysfunctions (depressive dementia),an adjustment dis-
turbance, or minor depressive syndrome.
73 Insidious
mode of onset,fluctuations in mood (irritability,loss of
emotional control),objective deficits on neuropsycho-
logical tests,normal self-image,and progression of cog-
nitive deficits point to primary dementia.
73,74
Treatment of depression in dementia comprises phar-
macotherapy and nonpharmacological strategies, such
as psychological interventions to enhance quality of life
(eg, emotion-oriented psychotherapy and stimulation-
oriented treatment, including art or social therapies,
exercise, and dance).
75 Developing a daily routine and
the institution of pleasant activities are considered first
step.
67 Simultaneously,the problem-solving skills of care-
givers should be enhanced and psychoeducational pro-
grams conducted. Sometimes psychotherapeutic inter-
ventions with family members are indicated.
Pharmacological treatment in aged patients with tradi-
tional antidepressants may evoke difficult clinical situa-
tions.Altered pharmacokinetics and pharmacodynam-
ics associated with aging, accompanying physical
disorders, as well as polypharmacy in the elderly, must
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Table VI. Examples for drug treatment of depression in patients with dementia. SSRI, selective serotonin reuptake inhibitor; RIMA, reversible inhibitor
of monoamine oxidase A; SNRI, serotonin and noradrenergic reuptake inhibitor; NaSSA, noradrenergic and specific serotonergic antidepres-
sant; NRI, norepinephrine reuptake inhibitor.
Class Compound Average dose (mg/day) Starting dose (mg) Comments
SSRI Citalopram
77 20–40 10
SSRI Sertraline
78 50–150 25
RIMA Moclobemide 75–450 75
SNRI Venlafaxine 37.5–150 37.5 Linear dose–response curve
NaSSA Mirtazepine 15–45 15 Sedative properties
NRI Reboxetine 2–62
Table VII. Common side effects of antidepressants. +, mild; ++, moderate; +++, strong; MAOI, monoamine oxidase inhibitor; TCA, tricyclic anti-
depressant.
Side effects TCAs SSRIs MAOIs Venlafaxine Mirtazepine Nefazodone Reboxetine
Anticholinergic +++ + 0 + + (+) +
Orthostatic hypotension +++ 0 + 0 + +(+) +
Hypertension 0 0 +(+) +(+) 0 0 +
Weight gain +++ + + + ++ + +
Gastrointestinal symptoms + ++ + ++ + + +
Sexual dysfunction +(+) ++ + ++ + + +
Toxicity in overdose +++ + +++ + + + +Behavioral disturbances in dementia - Müller-Spahn  Dialogues in Clinical Neuroscience - Vol 5 . No.1 . 2003
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Trastornos de conducta en la demencia
Los síntomas psicológicos y los trastornos de con-
ducta son características comunes y prominentes de
la demencia. Ellos incluyen síntomas como depresión,
ansiedad, psicosis, agitación, agresividad, desinhibi-
ción y trastornos del sueño. Aproximadamente un
80% a 90% de los pacientes con demencia sufren de
tales trastornos de conducta. Existen interacciones
complejas entre los déficits cognitivos, los síntomas
psicológicos y los trastornos de conducta. Se ha desa-
rrollado un gran número de instrumentos estanda-
rizados, confiables y bien validados para cuantificar
los síntomas conductuales y psicológicos de la
demencia, y así poder evaluar la eficacia del trata-
miento. Los procesos neurodegenerativos que ocu-
rren en diversas áreas cerebrales, especialmente en
la corteza fronto-temporal y en las regiones límbicas,
llevan a disfunciones de los neurotransmisores coli-
nérgicos, serotoninérgicos y noradrenérgicos, y de
ese modo constituyen la base biológica de los sínto-
mas conductuales; en cambio, los factores psicológi-
cos y los rasgos de personalidad tienen un rol modi-
ficador. Se ha desarrollado un gran número de
estrategias farmacológicas, psicoeducacionales, psi-
coterapéuticas y sociales para mejorar la calidad de
vida de los pacientes y de sus cuidadores. 
Troubles comportementaux de la démence
Les symptômes psychologiques et les anomalies com-
portementales constituent des caractéristiques à la
fois courantes et importantes de la démence. Ils
incluent des symptômes tels que la dépression,
l’anxiété, la psychose, l’agitation, l’agressivité, la
désinhibition et les troubles du sommeil. Environ 80
à 90 % des patients atteints de démence souffrent
de tels troubles comportementaux. Des interactions
complexes existent entre les déficits cognitifs, les
symptômes psychologiques et les anomalies du com-
portement. Un grand nombre d’outils standardisés,
fiables, et bien validés pour explorer les symptômes
comportementaux et psychologiques de la démence
ont été développés afin d’évaluer l’efficacité du trai-
tement. Les processus neurodégénératifs dans diffé-
rentes aires du cerveau, particulièrement dans le cor-
tex frontotemporal et les régions limbiques,
entraînant des dysfonctionnements des neurotrans-
metteurs cholinergiques, sérotoninergiques et nora-
drénergiques, forment la base biologique des symp-
tômes comportementaux, alors que les facteurs
psychologiques et  les traits de personnalité jouent
un rôle modificateur. Un grand nombre de stratégies
pharmacologiques, psychoéducationnelles, psycho-
thérapeutiques et sociales ont été développées pour
améliorer la qualité de vie des patients et de leurs
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